Supplemental Figure 1:

A



DT-382

B



DT-061

Supplementary Figure 1. SMAPs chemical structures. A, Chemical structure for DT-382. B, Chemical structure for DT-061

Supplemental Figure 2:



Supplementary Figure 2. PP2A activation induces cell death in EGFR-driven TKI-sensitive NSCLC cell lines. HCC827 and H3255 cell lines were treated with various concentrations of SMAP DT-061 for 48 hours, cell viability assay by cell counting.

Supplemental Figure 3:



Supplementary Figure 3. A, Chemical structure for DT-1310. B, Annexin V positivity at 24 hours in H1975 cells treated with 20 μM of DT-1310 in combination with ZVAD. Three independent experiments represented as mean ± SD. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001. C, Western blot analysis for pEGFR, EGFR, pAKT, AKT, pERK, ERK in H1975 treated with 20 μM of DT-1310 at 24 hours.

Supplemental Figure 4:



Supplementary Figure 4. A, TM00199 PDX model has low sensitivity to TKI afatinib. Tumor volume (mm3) in function of time in a PDX mouse model treated with either vehicle control, afatinib (5mg/kg) or SMAP DT-061 (5 mg/kg).